Company Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease.
In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States.
REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2008 |
| IPO Date | Sep 17, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 344 |
| CEO | Kenneth T. Mills |
Contact Details
Address: 9804 Medical Center Drive Rockville, Maryland 20850 United States | |
| Phone | 240-552-8181 |
| Website | regenxbio.com |
Stock Details
| Ticker Symbol | RGNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590877 |
| CUSIP Number | 75901B107 |
| ISIN Number | US75901B1070 |
| Employer ID | 47-1851754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kenneth T. Mills | President, Chief Executive Officer and Director |
| Vittal K. Vasista | Executive Vice President and Chief Financial Officer |
| Curran M. Simpson M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Olivier Danos Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Stephen Pakola M.D. | Executive Vice President and Chief Medical Officer |
| Patrick J. Christmas II, J.D. | Executive Vice President and Chief Legal Officer |
| Shiva G. Fritsch | Chief Communications and People Officer |
| Dr. Laura A. Coruzzi J.D., Ph.D. | Executive Vice President of Intellectual Property |
| Dr. Ram Palanki Pharm.D. | Executive Vice President of Commercial Strategy and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | ARS | Filing |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 424B5 | Filing |
| Mar 7, 2024 | FWP | Free Writing Prospectus |
| Mar 6, 2024 | 424B5 | Filing |
| Mar 5, 2024 | 144 | Filing |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 10-K | Annual Report |